HIV linked to lower rifampin and ethambutol AUCs in TB cohort

HIV Treat Bull - Vol. 7, No. 6, June 2006

HIV infection independently predicted lower rifampin and ethambutol exposure in a cohort of 142 people beginning first-line therapy for drug-sensitive pulmonary tuberculosis.

South African researchers measured 8-hour area under the concentration-time curve (AUC) for rifampin, isoniazid, pyrazinamide, and ethambutol after 2 months of daily in-hospital treatment. They used multiple linear regression to sort out variables associated with variation in AUCs.

HIV infection correlated with a 39% lower rifampin AUC and a 27% lower ethambutol AUC. Women had higher rifampin and isoniazid AUCs than men but lower ethambutol concentrations. Older patients had higher levels of isoniazid and ethambutol. Patients with a history of anti-TB therapy had lower ethambutol concentrations. And dose per kilogram of body weight correlated with AUCs of all four drugs.

The authors caution “further studies are required to assess the implications of variations in antituberculosis drug concentrations for efficacy and safety before decisions are made to change the dosing strategy in patients at risk.”

Ref: Helen McIlleron, Peter Wash, André Burger, Jennifer Norman, Peter I. Folb, Pete Smith. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemther 2006;50:1170-1177.

Source: HIVpharmacology.com (April 2006)

2006-06-10
IB060706-30

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.